Understanding Obesity as a Medical Condition
Obesity is a chronic, progressive metabolic disease - not a failure of willpower. This is one of the most important shifts in medical understanding over the past two decades. Research has conclusively demonstrated that obesity involves complex interactions between genetics, hormonal signaling, brain chemistry, gut microbiome composition, environmental factors, and metabolic adaptation. When a person gains weight and then attempts to lose it, the body actively fights to return to its higher weight through hormonal changes that increase hunger and reduce metabolic rate.
The statistics underscore the scope of the problem. Over 40% of American adults have obesity, and nearly 10% have severe obesity. Obesity significantly increases the risk of type 2 diabetes, cardiovascular disease, certain cancers, sleep apnea, joint disorders, and premature death. Traditional approaches - diet and exercise alone - produce meaningful long-term weight loss in fewer than 5% of patients, not because people lack discipline, but because the biological mechanisms working against weight loss are powerful.
This understanding has driven a fundamental rethinking of treatment approaches. Just as hypertension and diabetes are treated with medications that address their underlying biological mechanisms, obesity can now be treated with pharmacotherapy that targets the hormonal and neurological pathways driving excessive weight gain. Peptide therapy represents the most significant advancement in this area.
How Incretin-Based Preparations Are Used for Weight Management
Peptide therapy for weight management primarily works through incretin-based mechanisms. Incretins are gut hormones released after eating that regulate blood sugar, appetite, and metabolism. The two key incretins - GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) - are the targets of the most-studied incretin-based molecules.
GLP-1 receptor agonists like semaglutide act on satiety centers in the brain, slow gastric emptying to prolong fullness after meals, and improve insulin sensitivity. Dual GIP/GLP-1 agonists like tirzepatide engage both incretin pathways simultaneously. The FDA-approved finished products built around these molecules have substantial clinical-trial programs documenting their effects on body weight and metabolic markers.
GetPepWell dispenses compounded preparations of both molecules through a licensed pharmacy partner under physician supervision. The compounded preparations themselves are not FDA-approved finished products; outcomes from a compounded preparation are not guaranteed to match the finished-product trial results.
Which Preparations GetPepWell Offers
GetPepWell's weight-management catalog is scoped to two compounded preparations.
Compounded semaglutide uses the same API as the FDA-approved finished products Ozempic (for type 2 diabetes) and Wegovy (for chronic weight management). The finished products have been studied in the STEP clinical trial program for weight management and in the SELECT trial for cardiovascular risk reduction. Compounded semaglutide is administered as a once-weekly subcutaneous injection with gradual dose escalation under physician supervision.
Compounded tirzepatide uses the same API as the FDA-approved finished products Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). The finished products have been studied in the SURMOUNT trial program for weight management and the SURPASS program for type 2 diabetes. Compounded tirzepatide is also administered as a once-weekly subcutaneous injection with gradual dose escalation.
Your physician will evaluate which compounded preparation is most appropriate based on your medical history, BMI, metabolic markers, and weight-management goals. Compounded preparations are not FDA-approved finished products, and outcomes are not guaranteed to match the finished-product trial data.
Research Evidence
The clinical-trial evidence for these molecules is among the strongest in metabolic medicine. The STEP trial program for semaglutide and the SURMOUNT trial program for tirzepatide are large-scale, randomized, placebo-controlled studies published in the New England Journal of Medicine and other top-tier journals. Importantly, these trials were conducted on the FDA-approved finished products, not on any compounded preparation.
Beyond weight changes, the finished-product trials reported improvements across a range of obesity-related health markers in the studied populations, including reductions in blood pressure, improvements in cholesterol and triglyceride levels, better glycemic control, and reduced inflammatory markers. The SELECT cardiovascular outcomes trial studied semaglutide finished product in overweight or obese adults with established cardiovascular disease and reported cardiovascular benefit on its primary endpoint.
Long-term data from these finished-product trials also documented weight regain after discontinuation, reinforcing that excess body weight is a chronic condition requiring ongoing management. The compounded preparations dispensed by GetPepWell have not undergone equivalent finished-product efficacy or safety testing; the finished-product trial results should be read as evidence about the molecule and its mechanism, not as a guarantee of identical outcomes from a compounded preparation.
The GetPepWell Weight Management Approach
At GetPepWell, weight management is treated as a comprehensive medical program, not a simple prescription. The process begins with a detailed medical intake that assesses your weight history, previous weight loss attempts, eating patterns, activity level, sleep quality, stress factors, current medications, and any relevant medical conditions. This information helps your physician understand the full picture of your metabolic health.
Your physician consultation includes a review of lab work - typically including metabolic panel, lipid panel, thyroid function, HbA1c, and other relevant markers - to identify any underlying conditions contributing to weight gain or that may affect treatment selection. Based on this comprehensive evaluation, your physician recommends a personalized treatment plan that may include one or more peptide therapies along with guidance on nutrition, physical activity, and behavioral strategies.
Ongoing monitoring is a non-negotiable component of the program. Regular follow-up consultations allow your physician to track your progress, adjust dosing as needed, manage side effects, and ensure the treatment remains safe and effective. Weight management is a marathon, not a sprint, and the continuous physician oversight provided through GetPepWell is designed to support sustained, healthy weight loss over the long term.